Sarcopedia

MalignantSoft tissue

Synovial Sarcoma

Synonyms: Synovial cell sarcoma

t(X;18) EWSR1-SS18 fusion diagnostic

Quick Facts

Behaviour

Malignant

Category

Soft tissue

Grade

High

Synonyms

Synovial cell sarcoma

Category

Soft tissue

Behaviour

Malignant

Grade

High

Gender

Both equally

Tissue of Origin

Other

Epidemiology

  • Malignant sarcoma affecting adolescents and young adults
  • Peak incidence 2nd-3rd decades
  • Predilection for extremities
  • Monoarticular near large joints
  • t(X;18) EWSR1-SS18 translocation diagnostic

Clinical Features

  • Painful mass near large joint
  • Rapid growth
  • Limited joint motion
  • Constitutional symptoms if metastatic

Location

  • Knee (most common)
  • Ankle
  • Shoulder
  • Elbow
  • Wrist

Imaging

  • MRI: heterogeneous mass near joint
  • T2: cystic areas and hemorrhage common
  • Calcification rare but characteristic

Pathology

  • Biphasic (epithelial + spindle) or monophasic variants
  • t(X;18) EWSR1-SS18 fusion pathognomonic
  • SS18+ (nuclear immunostain)
  • High-grade sarcoma

Genetics

  • t(X;18)(p11;q11) EWSR1-SS18 90%
  • t(X;18)(p11;q11) EWSR1-SSX2 5-10%
  • Rare other rearrangements

Treatment

  • Wide surgical resection: primary treatment
  • Chemotherapy: neoadjuvant or adjuvant
  • Radiotherapy: adjuvant if margins inadequate

Prognosis

  • 60-70% 5-year survival with multimodal therapy
  • Stage and size prognostic factors
  • High metastatic potential

Key Points

  • t(X;18) EWSR1-SS18 fusion diagnostic
  • Multimodal therapy standard
  • High-grade malignancy despite small appearance

Workup - Blood Tests

FBC, U&E, LFTs, LDH

Workup - Local Imaging

  • MRI primary site: local staging
  • CT chest/abdomen/pelvis: metastatic staging
  • PET-CT: consider

Workup - Biopsy

Core needle biopsy: EWSR1-SS18 FISH confirmatory

Workup - Staging

CT chest/abdomen/pelvis: standard

Follow-up Summary

  • Year 1: Post-operative visit within first 6 weeks; 3–4 monthly clinical examination and CXR; image prosthesis at 6 months and 1 year
  • Year 2: 3–4 monthly clinical examination and CXR; image prosthesis annually
  • Years 3–4: 6-monthly clinical examination and CXR; image prosthesis annually
  • Years 5–10: Annual clinical examination and CXR; image prosthesis annually
  • Discharge at 10 years after treatment